Merck KGaA offloads clinical-phase cancer drugs to Day One

Merck KGaA has out-licensed two oral MEK inhibitors to Day One Biopharmaceuticals. The agreement positions Day One to test pimasertib in combination with its pan-RAF kinase inhibitor in a subset of solid tumor patients.